RBC
GSK icon

Ronald Blue & Co’s GSK GSK Stock Holding History

Ronald Blue & Co’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-5,042
Closed -$242K – 236
2015
Q3 		$242K Sell
5,042
-3,475
-41% -$181K 0.01% 247
2015
Q2 		$443K Sell
8,517
-785
-8% -$44.2K 0.02% 186
2015
Q1 		$536K Buy
9,302
+3,497
+60% +$200K 0.03% 157
2014
Q4 		$310K Sell
5,805
-4,218
-42% -$236K 0.02% 237
2014
Q3 		$576K Sell
10,023
-1,195
-11% -$73.3K 0.04% 140
2014
Q2 		$750K Buy
11,218
+1,602
+17% +$108K 0.05% 115
2014
Q1 		$642K Buy
9,616
+1,106
+13% +$74.8K 0.05% 123
2013
Q4 		$567K Buy
8,510
+773
+10% +$50.1K 0.04% 130
2013
Q3 		$485K Buy
7,737
+7,411
+2,273% +$477K 0.04% 130
2013
Q2 		$20K Buy
+326
New +$20.7K ﹤0.01% 206

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ronald Blue & Co's GSK Position: Q4 2015 in Review

Ronald Blue & Co sold out of GSK (GSK) in Q4 2015, closing a stake of 5,042 shares — an estimated $242K sold.

Ronald Blue & Co first reported a position in GSK in Q2 2013 and held it in 10 quarters. The position peaked at $750K in Q2 2014. 718 funds tracked by Wall St. Rank hold GSK as of Q4 2015.

  • Ronald Blue & Co reported no remaining GSK position as of Q4 2015 after selling out during the quarter.
  • Ronald Blue & Co sold 5,042 GSK shares in Q4 2015, an estimated $242K.
  • Ronald Blue & Co first reported a position in GSK in Q2 2013 and held it in 10 quarters.
  • Ronald Blue & Co's GSK position peaked at $750K in Q2 2014.
  • 718 funds tracked by Wall St. Rank held GSK as of Q4 2015.

Based on Ronald Blue & Co's 13F filing for Q4 2015, filed 11 Feb 2016.